Poor concordance between CA-125 and RECIST at the time of disease progression in patients with platinum-resistant ovarian cancer: analysis of the AURELIA trial.

MLA

Lindemann, K., et al. “Poor Concordance between CA-125 and RECIST at the Time of Disease Progression in Patients with Platinum-Resistant Ovarian Cancer: Analysis of the AURELIA Trial.” Annals of Oncology : Official Journal of the European Society for Medical Oncology, vol. 27, no. 8, Aug. 2016, pp. 1505–10. EBSCOhost, https://doi.org/10.1093/annonc/mdw238.

APA

Lindemann, K., Kristensen, G., Mirza, M. R., Davies, L., Hilpert, F., Romero, I., Ayhan, A., Burges, A., Rubio, M. J., Raspagliesi, F., Huizing, M., Creemers, G.-J., Lykka, M., Lee, C. K., Gebski, V., & Pujade-Lauraine, E. (2016). Poor concordance between CA-125 and RECIST at the time of disease progression in patients with platinum-resistant ovarian cancer: analysis of the AURELIA trial. Annals of Oncology : Official Journal of the European Society for Medical Oncology, 27(8), 1505–1510. https://doi.org/10.1093/annonc/mdw238

Chicago

Lindemann, K, G Kristensen, M R Mirza, L Davies, F Hilpert, I Romero, A Ayhan, et al. 2016. “Poor Concordance between CA-125 and RECIST at the Time of Disease Progression in Patients with Platinum-Resistant Ovarian Cancer: Analysis of the AURELIA Trial.” Annals of Oncology : Official Journal of the European Society for Medical Oncology 27 (8): 1505–10. doi:10.1093/annonc/mdw238.